Day 1 - Tuesday 14 May, 2019
Meeting category
Date(s)
14 May 2019 - 16 May 2019
Location
Noordwijk,
Netherlands
Organizer
Titanium Level Support
Sponsor logos
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Related Enduring Materials
Enduring Materials
Opening of the workshop - 16:00
16:00 CEST
Opening Remarks
David Burger, PharmD, PhD
Radboud University Medical Centre, the Netherlands
Session 1 - 20 Years in Review - 16:15
Marta Boffito, MD, PhD, FRCP, MBA
16:15 CEST
Drug-drug interactions: all you need to know beyond www.hiv-druginteractions.org
Chelsea and Westminster Hospital NHS Foundation Trust; Imperial College London; United Kingdom
16:45 CEST
Stop measuring ARV levels in plasma!
17:15 CEST
50% adherence is enough with modern ARVs, right?
17:45 CEST
Modern ARVs do not develop resistance, do they?
Day 2 - Wednesday 15 May 2019
Abstract-driven Presentations - 09:00
09:00 CEST
Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine #1
Anthony Podany, PharmD
University of Nebraska Medical Center, United States
09:15 CEST
In silico design of a microarray patch as a multipurpose prevention technology #2
Rajith Rajoli
Univerisity Of Liverpool, United Kingdom
09:30 CEST
Population pharmacokinetics of VRC01 in infants and adults #3
Jerry Li
University of California San Diego, United States
09:45 CEST
The initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects #4
Samit Joshi, MD
ViiV Healthcare, United States
Session 3: Viral Hepatitis & Liver Disease -
Alice Tseng, B.Sc.Phm., PharmD, FCSHP, AAHIVP
Chairs
Toronto General Hospital, University of Toronto, Canada
11:00 CEST
Novel antiviral and immune targets to cure HBV
Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare -
Opening Remarks
Chair: Jonathan Schapiro, MD
Sheba Medical Center, Israel
12:00 CEST
Improved long acting drug delivery: What are the technologies?
12:20 CEST
Long acting HIV drugs for treatment: Data and potential implementation
12:40 CEST
Long Acting HIV Drugs for Prevention: Data and Potential implementation
Session 4 - Drug-drug interactions: evolving challenges -
Angela DM Kashuba, BScPhm, PharmD, DABCP, FCP
Catia Marzolini, PharmD, PhD
Chairs
University of North Carolina, Chapel Hill, United States
14:00 CEST
Clinical Case Presentation
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
14:30 CEST
ClinicalCasesDDI Website Launch
José Moltó, MD, PhD
-
Abstract-driven Presentations - 14:40
14:40 CEST
Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website #5
Sara Gibbons
University of Liverpool, United Kingdom
14:55 CEST
Drugs abuse and chemsex: a new challenge for antiretroviral drug-drug interaction #6
Tess Martin
APHM La Timone, France
15:10 CEST
Effect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy
Michelle Pham
University Of Nebraska Medical Center
Debate: Dual maintenance for HIV: Why fix it if it's not broken? - 16:15
16:15 CEST
Moderator: Jonathan Schapiro
Pro Perspective
José Ramón Arribas, MD
Con Perspective
Andrew Hill, MD
Special Lecture - 17:00
17:00 CEST
Regulatory perspective on evaluating ARVs in during pregnancy
Kimberly Struble, PharmD
US Food & Drug Administration, United States
Day 3 - Thursday 16 May
Session 5 - Special populations and adherence -
Chairs
08:30 CEST
Special Presentation: Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)
Paul Domanico, PhD
Clinton Health Access Initiative, United States
08:45 CEST
Infant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1
Laura Dickinson
University Of Liverpool, United Kingdom
09:00 CEST
Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum
Jeremiah Momper
University Of California San Diego, United States
09:15 CEST
Low isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment
Marije Van Schalkwyk, MD
Stellenbosch University, South Africa
09:30 CEST
Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum
Kristina Brooks, PharmD
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States
09:45 CEST
Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy
10:00 CEST
An exploration of adherence measures to detect recent changes in Truvada® dosing patterns
Short Poster Presentations; "Best of Posters" -
Moderator
Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV
Felix Stader
University Hospital Basel, Switzerland
Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy
Mary Gockenbach
US Food and Drug Administration, Division of Pediatrics and Maternal Health
A semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescents
Bernard Ngara
University Of Zimbabwe College Of Health Sciences, Zimbabwe
Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir
Aarti Patel
Glaxosmithkline R&D, United Kingdom
The Next 20 Years -
CRISPR/Cas and gene editing for HIV
Paula Cannon, PhD
University of Southern California Keck School of Medicine, United States
Chairs
11:30 CEST
CRISPR/Cas and gene editing for HIV
Paula Cannon, PhD
University of Southern California Keck School of Medicine, United States
12:00 CEST
Understanding the key determinants of performance for long-acting formulations
Closing Remarks
Overview
Welcome
On behalf of the Organizing Committee, we would like to express our appreciation for your dedicated participation at the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs.
We would like to give a special thank you to our sponsors ViiV Healthcare, Gilead Sciences, Arbutus Biopharma and Merck for making this event possible!
We thank you for your attendance and participation and hope to see you again next year!
Practical Information
Language
The official language of the workshop was English. Translation was not provided.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Committees
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
Support
Media
Noordwijk 2000
Image
Noordwijk 2019
Image
Language
Related Programs
